Popular nonprescription acne treatment
products can cause serious and potentially life-threatening hypersensitivity
reactions such as tightness in the throat, swelling in the face, difficultly
breathing, and fainting.
by John
Tyburski
Copyright © Daily
Digest News, KPR Media, LLC. All rights reserved.
According to
a Drug Safety Communication
issued on Wednesday by the U.S. Food and Drug Administration (FDA),
over-the-counter (OTC) topical acne products can cause serious and even
life-threatening allergic reactions, both at the application sites and
systemically. The drugs are already labeled with a caution of redness, itching,
peeling, dryness, burning, or mild swelling at the application site, but the
new symptoms point to much more serious, albeit rare hypersensitivity
reactions.
The safety
announcement advises consumers to stop using the OTC acne products and
immediately seek emergency medical attention if they experience one or more of
the following symptoms: faintness, tightness in the throat, difficulty in
breathing, or swelling of the face, lips, tongue, or eyes. Less serious
reactions such as hives or itching may also occur, indicating as well that
consumers should stop using the products immediately.
The products
identified in the announcement contain the active ingredients benzoyl peroxide
or salicylic acid. The active ingredients are included on the product labels.
Drugs that contain these are marketed under a variety of brand names including
Ambi, Aveeno, Clean & Cear, MaxClarity, Neutrogena, Oxy, and Proactiv.
These products are sold in a variety of forms including gels, lotions,
solutions, washes, pads, toners, and scrubs.
“There is
currently no mention of the possibility of these very severe allergic reactions
on the product labels,” said Dr. Mona Khurana, a medical officer at FDA, in a
FDA statement. “It’s important that consumers know about them, and that they
know what to do if they occur.”
At this
time, the FDA has not determined which of ingredients of the OTC acne products
are responsible for causing the serious allergic reactions. It remains possible
that one or more inactive ingredients or a combination of active and inactive
ingredients causes the serious hypersensitivity reactions. The reactions may
occur within minutes after applying the product but may otherwise take a day or
longer to develop.
The decision
to release the safety announcement came after the regulatory agency had received
131 reports of serious allergic reactions from both consumer and manufacturer
sources. The majority of these reports are recent, having been made since 2012.
Although no deaths have been reported, 44 percent of the patients required
hospitalization.
New users of
these products are advised to test them on a small area of skin and monitor for
adverse reactions for three days. If no complications develop, then consumers
may use the product according to the manufacturer’s directions printed on the
packaging.
No comments:
Post a Comment